Accelerating Structure-based Drug Design for Complex Membrane Proteins
Nuclera and leadXpro partnership will deliver AI-guided end-to-end workflow to access challenging membrane protein targets
-
1
Nuclera and leadXpro have partnered to enhance drug discovery for complex membrane proteins using AI/ML and rapid screening technologies.
-
2
Membrane proteins are valuable drug targets but are difficult to express and purify, hindering structural biology studies.
-
3
The collaboration aims to create an AI-guided workflow that integrates construct design with experimental multiplex screening.
-
4
Promising membrane protein constructs will undergo biophysical characterization and cryo-EM structure determination.
-
5
The partnership seeks to embed AI/ML capabilities into Nuclera’s system to expedite the transition from sequence to structural insights.
